Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Dow
Baxter
McKinsey
Mallinckrodt

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Details for Patent: 8,415,355


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,415,355
Title:Pyrrolopyrimidine compounds and their uses
Abstract: The present invention relates to compounds of formula (I) and to pharmaceutically acceptable salts and pharmaceutical compositions thereof. The present invention also relates to use of the compounds of formula (I) in modulating the activity of protein kinases and in the treatment of disease, particularly a disease, disorder or syndrome associated with CDK 4 inhibition. ##STR00001##
Inventor(s): Brain; Christopher Thomas (Cambridge, MA), Sung; Moo Je (Cambridge, MA), Lagu; Bharat (Acton, MA)
Assignee: Novartis AG (Basel, CH) Astex Therapeutics Ltd. (Cambridge, GB)
Application Number:12/545,322
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form;

Recent additions to Drugs Protected by US Patent 8,415,355

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Novartis KISQALI ribociclib succinate TABLET 209092 Mar 13, 2017 RX Yes ⤷  Sign up for a Free Trial Y Y ⤷  Sign up for a Free Trial
Novartis KISQALI FEMARA CO-PACK (COPACKAGED) letrozole; ribociclib succinate TABLET 209935 May 4, 2017 RX Yes ⤷  Sign up for a Free Trial Y Y ⤷  Sign up for a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 8,415,355

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis KISQALI ribociclib succinate TABLET;ORAL 209092-001 Mar 13, 2017 RX Yes Yes ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial Y Y ⤷  Sign up for a Free Trial
Novartis KISQALI FEMARA CO-PACK (COPACKAGED) letrozole; ribociclib succinate TABLET;ORAL 209935-001 May 4, 2017 RX Yes Yes ⤷  Sign up for a Free Trial ⤷  Sign up for a Free Trial Y Y ⤷  Sign up for a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,415,355

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 073116 ⤷  Sign up for a Free Trial
Argentina 111763 ⤷  Sign up for a Free Trial
Australia 2009284098 ⤷  Sign up for a Free Trial
Brazil PI0917791 ⤷  Sign up for a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Express Scripts
Moodys
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.